Brian Mehling

Founder and CMO

Brian Mehling, M.D., M.S. is the founder and chief medical officer of Blue Horizon International (BHI). He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy through his company, Blue Horizon International, a healthcare consulting organization focused on treatment and research using stem cells and exosomes. He is board-certified in orthopedic surgery and anti- aging/regenerative medicine.
Dr. Mehling started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University.
Completing his degree of medicine at Wright State University School of Medicine, Dr. Mehling received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA. He is currently pursuing a Ph.D. in Chemistry at Seton Hall University.
An orthopedic trauma surgeon, Dr. Mehling operates his own practice, Mehling Orthopedics, in Hackensack, NJ.
Dr. Mehling has traveled extensively throughout Asia and the Middle East observing first-hand the differences in healthcare standards. Identifying the need for a universal high-quality standard, he founded Blue Horizon International.
He and his colleagues have successfully treated and monitored more than 600 patients using stem cell and regenerative therapies.
Dr. Mehling founded the Blue Horizon Charitable Foundation, which was with the mission to assist in and finance the advancement of all aspects of stem cell therapies and cellular regenerative medicine and research in full regulatory conformance, in conjunction with the scientific community. The foundation will also support and provide charitable therapies to those suffering from degenerative diseases and debilitating conditions.